Survival benefit from frontline immunotherapy in progression-free non–small cell lung cancer peaks at 2 years
For patients who are progression-free after two years of frontline immunotherapy for advanced non–small cell lung cancer (NSCLC), there does not appear to be a survival benefit in… read more.
